Yanashima Kensuke, Furukawa Yoshiki, Ishii Midori, Kinoshita Shintaro, Hamano Yasuharu, Watanabe Naoki, Tsukune Yutaka, Yasuda Hajime, Ando Jun, Ando Miki
Department of Hematology Juntendo University School of Medicine Tokyo Japan.
Division of Cell Therapy & Blood Transfusion Medicine Juntendo University School of Medicine Tokyo Japan.
EJHaem. 2025 Jun 17;6(3):e70079. doi: 10.1002/jha2.70079. eCollection 2025 Jun.
Bispecific antibodies are effective for relapsed/refractory B-cell lymphoma patients even after CAR-T therapy.
Peripheral blood CAR-T kinetics and functional analysis in vivo were carried out pre- and post-epcoritamab infusion in B-cell lymphoma patients relapsing after CAR-T therapy.
CAR copy numbers spiked at relapse and rose again following epcoritamab administration. Expression levels of CAR-T exhaustion markers did not increase, whereas perforin and granzyme B expression increased after epcoritamab induction.
Early epcoritamab administration without cytotoxic agents at relapse after CAR-T therapy revives CAR-T cell numbers and cytotoxicity, which may potentially lead to favorable clinical outcomes.
双特异性抗体对复发/难治性B细胞淋巴瘤患者有效，即使在接受CAR-T治疗后也是如此。
在接受CAR-T治疗后复发的B细胞淋巴瘤患者中，在输注epcoritamab前后进行外周血CAR-T动力学及体内功能分析。
CAR拷贝数在复发时激增，并在给予epcoritamab后再次上升。CAR-T耗竭标志物的表达水平没有增加，而穿孔素和颗粒酶B的表达在epcoritamab诱导后增加。
在CAR-T治疗后复发时早期给予epcoritamab且不使用细胞毒性药物可恢复CAR-T细胞数量和细胞毒性，这可能会带来良好的临床结果。
